CBD is at the forefront of pharmacology. So why has the European Commission changed its recommended status to “Narcotic”? Read on to find out more.
Here, Evolve Ltd’s Managing Director, Christopher Busuttil Delbridge, takes us progressively deeper into what it takes to ensure regulatory compliance for Medical Cannabis.
Hannah Deacon, co-founder of Maple Tree Consultancy, explores how COVID is elevating and shaping the medical application of CBD.
Here, Professor Mike Barnes discusses and answers some key questions about the world of CBD in the UK.
Josep Figueras and Anna Sagan from the European Observatory on Health Systems and Policies focus here on antimicrobial resistance and ponder whether or not this could be the next big pandemic.
Renata Mala, PharmD, Chairman of Purely Plant GmbH, underlines the importance of ensuring high and reproducible quality when it comes to medicinal cannabis.
Here, we learn how Mile High Labs, a leading processor of hemp-derived cannabinoids, have raised Series B equity financing and are preparing for global CPG partnerships.
Kathleen Denoodt continues to enlighten us on the subject of medical cannabis, particularly imports to Germany and the Netherlands.
A new public health app by DRUID® measures factors to give an overall score of impairment, evolving the classic idea of drug testing.
Professor Tilmann Weber discusses how microbial genomics helps to find the next generation of antibiotics in the race against antimicrobial resistance.
Savage Cabbage Ltd offer their expertise to explain what cannabidiol (CBD) is and how it works: Read on to find out their perspective.
Associate, David Hardstaff and Partner, John Binns at BCL Solicitors LLP, explain here how cannabis wonder child takes a knock in light of the European Commission’s ‘pause’ on CBD novel food applications mean for this booming industry.
Janosch Kratz discusses the importance of medical cannabis for chronic pain diseases.
Chair of the European Medicinal Cannabis Association (EUMCA) issues warning that raising limit for THC in CBD to 0.3% will risk patient safety.
Dr David Moorhouse, General Neurologist, discusses the way that different diseases respond to different types of medical cannabis.
Dr Daniela Tonucci, a consultant for over 10 years, talks us through the use of cannabinoids as pain medicine.
Professor Trevor Jones, Chair at the European Medicinal Cannabis Association, speaks to Nishat about their plans for EU patient access to medicinal cannabis.
David Shurtleff, PhD, Deputy Director at the National Center for Complementary and Integrative Health, National Institutes of Health, discusses new funding opportunities for cannabinoid research.
Here, we learn how about a different kind of green crop that grows in Ireland and the journey of that from seed to shelf as part of the Greenheart CBD story.
In the last six months GreenLight Medicines has successfully out-licenced leads from its research, branching out internationally and attracting major investors.